Cart
sales@molnova.com
STX-478
CAS No. 2883540-92-7
STX-478( —— )
Catalog No. M37154 CAS No. 2883540-92-7
STX-478 is an orally active and selective PI3Kα inhibitor that penetrates the blood-brain barrier and has anticancer activity to inhibit tumor growth.STX-478 is indicated for the study of breast cancer and other cancers.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 514 | Get Quote |
|
| 5MG | 816 | Get Quote |
|
| 10MG | 1292 | Get Quote |
|
| 25MG | 2548 | Get Quote |
|
| 50MG | 4076 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSTX-478
-
NoteResearch use only, not for human use.
-
Brief DescriptionSTX-478 is an orally active and selective PI3Kα inhibitor that penetrates the blood-brain barrier and has anticancer activity to inhibit tumor growth.STX-478 is indicated for the study of breast cancer and other cancers.
-
DescriptionSTX-478 (compound 80) is an oral CNS-penetrant allosteric mutant-selective PI3Kα inhibitor. STX-478 shows robust and durable tumor regression and can be used in cancer research.
-
In VitroImmunofluorescence Cell Line:MCF10A cells Concentration:0-10,000 nM Incubation Time:1 h Result:Targeted the MCF10A cells (with the H1047R kinase domain mutation).
-
In VivoAnimal Model:Female BALB/c nude mice (CAL-33 xenograft model).Dosage:30, 100 mg/kg Administration:Oral administration Result:Showed a dose-dependent reduction in tumor volume.
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
RecptorPI3K
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2883540-92-7
-
Formula Weight401.29
-
Molecular FormulaC16H12F5N5O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (622.99 mM; Ultrasonic )
-
SMILES[C@H](NC(NC=1C=NC(N)=NC1)=O)(C(F)(F)F)C2=C(C)C=3C(O2)=C(F)C=C(F)C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. JR David St Jean, et al. Urea derivatives which can be used to treat cancer. Patent WO2022265993A1.
molnova catalog
related products
-
TGR-1202 R-enantiome...
TGR-1202 R-enantiomer is is the less active enantiomer of TGR-1202 (Umbralisib), TGR-1202 is a potent, selective, orally available PI3Kδ inhibitor with IC50 of 22 nM.
-
5S rRNA modificator
5S rRNA modificator, used in 5S rRNA RNA modification, is a suitable electrophile for 2’-hydroxyl acylation on structured RNA molecules.
-
iMDK
iMDK quarterhydrate is a potent PI3K inhibitor that inhibits the growth factor MDK (also known as midkine or MK). iMDK quarterhydrate synergistically inhibits non-small cell lung cancer (NSCLC) with MEK inhibitors without harming normal cells and mice.
